Purpose Irinotecan and thalidomide are commonly administered antineoplastic drugs. Combination treatment may potentiate their antitumor eVect and protect against irinotecan's intestinal toxicity. We investigated whether thalidomide can modulate the pharmacokinetics of irinotecan and metabolites. Methods The study employed a crossover design in which advanced solid tumor patients were randomized to two arms and treated with irinotecan 350 mg/m 2 intravenously (IV) every 3 weeks and thalidomide orally (p.o.) 400 mg daily. Pharmacokinetic data when irinotecan was administered as a single agent in each arm were compared to data when the two study agents were co-administered using paired t tests. Eighty percent and 90% conWdence intervals for the true diVerence were also calculated. Results The diVerences in pharmacokinetic parameters and metabolic markers after thalidomide administration were small and unlikely to be clinically signiWcant. With the exception of APC T 1/2 , none of the upper conWdence limits exceeds a 50% increase. Conclusions This study did not Wnd any clinically meaningful eVects of thalidomide on the pharmacokinetics of irinotecan or its metabolites.
Introduction
Irinotecan has complex pharmacokinetics, and it has been suggested that inhibition of the biliary excretion of SN-38, its active metabolite, may reduce the risk of severe diarrhea [1] . Studies of thalidomide in combination with irinotecan have reported an absence of severe diarrhea when both drugs are combined [2] [3] [4] [5] [6] [7] [8] . Mechanistic studies in rats showed that thalidomide can inhibit intestinal production of proinXammatory cytokines and TNF-alpha mRNA expression, leading to reduction of intestinal epithelial apoptosis induced by irinotecan [9] . Thalidomide also inhibited hepatobiliary and intestinal transport of irinotecan, SN-38, and SN-38 glucuronide (SN-38G) in rats [6, 7, 9] . To investigate whether thalidomide had a clinically relevant eVect on the pharmacokinetics of irinotecan and metabolites, we conducted a small randomized clinical study with a crossover design in patients with advanced solid tumors.
Materials and methods

Patient selection
Adult patients (¸18 years of age) with metastatic or unresectable malignancy and for which standard curative or palliative measures do not exist or are no longer eVective were included. Eligible patients had a Karnofsky performance status ¸70% and normal organ and marrow function. Patients receiving active therapy for seizures (enzymeinducing anticonvulsants) were excluded. The study was conducted under a National Cancer Institute (NCI) Investigational New Drug (IND) application for thalidomide. The trial was approved by the Institutional Review Board of the University of Chicago, and patients gave written informed consent prior to study enrollment.
Treatment plan
Irinotecan and thalidomide were supplied by the US National Cancer Institute. Irinotecan was administered IV as a 90-min infusion at a dose of 350 mg/m 2 every 3 weeks. Thalidomide was given orally at 400 mg per day. Patients were randomized to receive therapy on either arm A or arm B. The Wrst 42 days of treatment were considered cycle 1 of arm A, and the Wrst 47 days of treatment (day ¡6 to day 42) were considered the Wrst cycle of arm B. All patients received irinotecan on days 1 and 22. Patients on arm A received thalidomide on day 15 through day 28. Patients on arm B were treated with thalidomide on day ¡6 through day 7.
Pharmacokinetic sampling and methods
Patients had blood samples drawn on days 1 and 22 before the start of irinotecan administration and at 0.5, 1, 1.5, 2, 4, 6, 8, 24, 48, and 168 h after the start of infusion. Irinotecan and its metabolites were analyzed as previously described [10] .
The area under the plasma concentration-time curve from 0 to 24 h (AUC 0-24 h ), maximum plasma concentration (C max ), and half life (T 1/2 ) were estimated by noncompartmental methods using PK Solutions software (version 2.0, Summit Research Services, Montrose, CO). The biliary index (BI), a putative metric for SN-38 AUC in the bile, was calculated as AUC irinotecan ·(AUC SN-38 / AUC SN-38G ). The relative extent of glucuronidation (GR), a marker for uridine diphosphate glucuronosyltransferase (UGT) activity, was calculated as AUC SN-38G /AUC . The relative extent of conversion of irinotecan to SN-38 (REC) and metabolic ratio (MR) were determined as REC = AUC SN-38 /AUC irinotecan and MR = (AUC SN-38 + AUC SN-38G )/AUC irinotecan .
Statistical methods
The sample size was chosen to provide suYcient power to detect a 50% increase in the levels of SN-38G when thalidomide is co-administered with irinotecan compared to irinotecan alone, on the assumption that if thalidomide inhibits SN-38's biliary excretion, this should lead to an increased concentration of SN-38's major metabolite, SN-38G. Assuming a coeYcient of variation of 30%, a targeted sample size of 12 evaluable patients (6 each in arms A and B) would provide 90% power to detect an eVect of this magnitude, using a paired t test. For each patient, pharmacokinetic data obtained when irinotecan was being administered as a single agent [day 1 (Arm A) and day 22 (Arm B)] were compared to data when the two study agents were co-administered [day 22 (Arm A) and day 1 (Arm B)]. Pharmacokinetic data from both arms were then pooled for statistical analysis. ConWdence intervals (80 and 90%) for the observed diVerence were also calculated.
Results
Twenty-one patients were enrolled. Due to diYculties in accrual, the trial was terminated after ten of them were evaluable for pharmacokinetics. Reasons for non-evaluability included death, disease progression/relapse during active treatment, and patient withdrawal/refusal after beginning therapy. Pharmacokinetic data from two additional patients were not utilized: one arm B patient did not have blood drawn after day 22 (at 24 and 48 h), and one arm A patient had abnormally high SN-38 concentrations on day 1 (AUC 0-24 h = 1.068 h mg/l). The eVect of thalidomide on the pharmacokinetics of irinotecan and metabolites was therefore tested in 8 patients (3 in arm A and 5 in arm B). No statistically signiWcant diVerences (P > 0.05) were observed in pharmacokinetic parameters or metabolic markers when irinotecan was co-administered with thalidomide ( Table 1 ). Due to the small sample size, we also present 80% and 90% conWdence intervals. With the exception of APC T 1/2 , none of the upper conWdence limits exceeds a 50% increase. (For example, for SN-38G AUC, the upper 90% conWdence limit corresponds to a 24% increase.) One of eight patients developed grade 3 diarrhea. Grade 1 or 2 diarrhea was experienced by three patients.
Discussion
The administration of thalidomide with irinotecan had no clinically signiWcant eVect on the pharmacokinetics or metabolism of irinotecan in our randomized clinical trial. Two other cancer trials have examined the eVects of thalidomide on irinotecan's pharmacokinetics, with opposite outcomes. The lack of pharmacokinetic interaction we observed is consistent with results from a study of 17 patients with refractory malignancies. The trial compared pharmacokinetics of irinotecan and metabolites after administration of irinotecan alone (day 1, 125 mg/m 2 ) and in combination with thalidomide (day 22, 400 mg or 200 mg daily starting on day 3), and concluded there was no drug interaction [11] . This study and our research excluded patients receiving hepatic enzyme-inducing anticonvulsants to avoid an increase in metabolite formation: SN-38G via UGT1A1 [12] and APC via CYP3A4 [13] . A second study of 16 evaluable patients reported increased SN-38 AUC, BI, and REC, and decreased SN-38G AUC and GR during the second drug cycle (no thalidomide) [14] . The diVerent results of the latter study may be due to the nonrandomized design and confounding by co-administered drugs (phenytoin, phenobarbital, and dexamethasone were administered to approximately half the patients). Our study provides further evidence of the lack of a clinically relevant eVect of thalidomide on the pharmacokinetics of irinotecan and metabolites and the beneWts of randomized clinical trials to test pharmacokinetic questions. Although the number of evaluable patients was small, the conWdence limits for the magnitude of change did not suggest a meaningful eVect. However, due to the small cohort size, we did not address the potential beneWt of thalidomide on the toxicity or eYcacy of irinotecan. 
